Sangamo Therapeutics Missed Consensus Estimates
Monday, May 12, 2025 at 4:00 PM ET
Sangamo Therapeutics (SGMO) reported a loss of $0.14 per share on revenue of $6.44 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.11 per share on revenue of $9.17 million. The company missed consensus estimates by 27.27% while revenue grew 1,238.25% on a year-over-year basis.
Sangamo BioSciences Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development & commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs.
Earnings Whisper Grade
Power Rating
-
-
Reported Earnings
$-0.14
Earnings Whisper®
-
Consensus Estimate
$-0.11
Earnings Surprise
Earnings Growth
Reported Revenue
$6.44 Mil
Revenue Estimate
$9.17 Mil
Revenue Surprise
Revenue Growth